About
Accomplished leadership backed by trusted advisory boards.
LEADERSHIP
FOUNDER · CEO · CSO
Frank H. Lau MD, FACS
Harvard-trained plastic surgeon, 11+ years in clinical practice
Principal Investigator on 17 clinical studies
Developed the ex vivo human fat technology underpinning Lipovectra’s platform
Serial entrepreneur; founder of Firecracker (acquired by Wolters Kluwer)
Harvard Combined Plastic Surgery University of Michigan Medical School Yale
CHIEF BUSINESS &
COMMERCIAL STRATEGY OFFICER
Fauad Hasan
Founder & former CEO of Bonti (Now AbbVie)
Inventor of single-use bioreactor technology; holds multiple patents in bioprocessing and drug development.
25+ years scaling global franchises
Active Board member, advisor and consultant in biotech, investment funds & medtech accelerators with focus on therapeutics, clinical research, and medical aesthetics.
clinical design program manager
Elvira Chiccarelli, MD
Board-Certified Obesity Medicine Specialist
Led the US Defense Health Agency's Clinical Practice Guidelines for Obesity
Designed pharmacy benefit structures, led multidisciplinary weight management clinics, and directed health system compliance
Former USAF Medical Doctor & Assistant Professor at Uniformed Services University; Tulane MD and Adolescent Medicine Fellow at Fort Sam Houston
FOUNDER · CHAIRMAN
Alfred Scheidegger, PhD
Created and scaled global venture capital firm Nextech Invest
Led global bio-active compound R&D at Ciba-Geigy
Trained with Werner Arber (1978 Nobel Prize)
CEO, chairman, and active international board member
Harvard Business School PhD Microbiology/Biochemistry, University of Basel
chief of staff
Jesse Hartley
Strategic operations leader and force multiplier
Led multi-disciplinary teams on U.S. government initiatives requiring Top Secret clearance
Drove global execution for international operating companies exceeding $80M gross revenue
director of toxicology
David Hollenback, PhD
Strategic toxicology and drug development leader with extensive experience advancing small molecules, peptides, and biologics from discovery through clinical evaluation.
Served most recently as Director of Toxicology at Rubedo Life Sciences, with prior leadership roles at Gilead Sciences, Amgen, and SNBL USA.
Specializes in nonclinical safety strategy, CRO oversight, enterprise-wide in vivo practices, and regulatory filings (INDs, IBs, DSURs) across oncology, neurology, fibrosis, and metabolic disease.
FOUNDER · chief legal officer
Jason Bourgeois, JD
Patent licensing & litigation expert with biomedical licensing track record
Registered patent attorney; inventor on 8 patents
Co-Founder Keliomics Inc.; Founder IP Valuation Partners
Tulane Law School · Biomedical Engineering, Georgia Tech
executive director of cmc
Charles Cabral
Agile biologics program CMC and technical leader
Led Kostaive mRNA vaccine CMC from pre-clinical dev to commercial launch at Arcturus, CleanCap commercial scale-up to meet global Cominarty vaccine demand at TriLink
18 years experience driving complex biologics programs including mRNA, plasmids, 5' cap molecules, enzymes, and peptides.
Prior experience includes Arcturus Therapeutics, Vical, and Thermo Fisher Scientific
Advisors
BUSINESS & STRATEGY
Michael Davitz MD, JD
Biotechnology prosecution & strategic counseling
Patent Trial and Appeal Board
Leason Ellis LLP
SCIENTIFIC & CLINICAL
Adrian Dobrescu, MD, MS, FAAD
Double Board Certified in Dermatology and Micrographic Dermatologic Surgery (Mohs)
Founder of cosmetic and procedural dermatology practices
Experienced clinical investigator
Alan M. Fisch, JD
One of "The Leading 500 Lawyers in America"
Top intellectual-property litigator
Fisch Sigler LLP
Carrie E. McCurdy, PhD
Associate Professor, food studies & human physiology
Obesity and insulin resistance
University of Oregon
Aaron Greenstone, JD
Senior CIA Operations Officer
Trial attorney
23+ years of experience